Champions Oncology director Ackerman exercises options

Ackerman's reported direct common-stock holdings after the exercise were 1,126,333 shares.

Rhea-AI Filing Summary

Champions Oncology, Inc. (CSBR) director Joel Ackerman exercised options covering 69,794 shares of common stock on October 15, 2026, at an exercise price of $1.60 per share. The transaction reported acquisition of 69,794 common shares, bringing his directly held common-stock position to 1,126,333 shares; the option position was reported as 0 following the exercise.

Insider Trade Summary

69,794 shares exercised/converted

Exercise 2 txns

Insider ACKERMAN JOEL

Role Director

Type	Security	Shares	Price	Value
Exercise	Option to purchase Common Stock F1	69,794	$1.60	$112K
Exercise	Common Stock	69,794	$1.60	$112K

Holdings After Transaction: Option to purchase Common Stock — 0 contracts (Direct); Common Stock — 1,126,333 shares (Direct)

Footnotes (1)

1. F1. The Options vest and are exercisable over a twelve month period, with vesting to occur on January 31, 2017, April 30, 2017, July 31, 2017 and October 31, 2017, respectively.

Key Figures

Options exercised: 69,794 options Exercise price: $1.60 per share Common shares acquired: 69,794 shares +2 more

5 metrics

Options exercised 69,794 options October 15, 2026

Exercise price $1.60 per share Options exercised October 15, 2026

Common shares acquired 69,794 shares October 15, 2026

Direct common-stock holdings after transaction 1,126,333 shares Following the October 15, 2026 transaction

Option position following transaction 0 options Following the October 15, 2026 transaction

Key Terms

Option to purchase Common Stock, exercise price, vesting

3 terms

Option to purchase Common Stock financial

"Option to purchase Common Stock"

exercise price financial

"exercise price of $1.60 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"vesting to occur on January 31, 2017"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CSBR options did Joel Ackerman exercise, and at what price?

Joel Ackerman exercised options covering 69,794 common shares at $1.60 per share on October 15, 2026. The transaction also reported acquisition of 69,794 common shares.

How many CSBR shares did Joel Ackerman hold after exercising the options?

Joel Ackerman's reported direct common-stock holdings after the exercise were 1,126,333 shares. The option position was reported as 0 following the exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/16/2026 - 12:45 PM EDT Accepted by SEC EDGAR 10/16/2026 - 12:45 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ACKERMAN JOEL

(Last) (First) (Middle)

C/O CHAMPIONS ONCOLOGY, INC.

ONE UNIVERSITY PLACE, SUITE 307

(Street)

HACKENSACK NEW JERSEY 07601

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CHAMPIONS ONCOLOGY, INC. [ CSBR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/15/2026		M		69,794	A	$1.6	1,126,333	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase Common Stock	$1.6	10/15/2026		M			69,794	(1)	10/31/2026	Common Stock	69,794	$1.6	0	D

Explanation of Responses:

1. The Options vest and are exercisable over a twelve month period, with vesting to occur on January 31, 2017, April 30, 2017, July 31, 2017 and October 31, 2017, respectively.

Remarks:

	/s/ Joel Ackerman	10/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)